Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.regeneron.com
Regeneron Pharmaceuticals Inc. News Releases
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 253 followers
Latest posts
Last updated 5 days ago
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
5 days ago
TARRYTOWN, N.Y. , June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
7 days ago
Initiative aims to expand and encourage philanthropy to help patients with retinal...
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
11 days ago
Approval based on pivotal results showing improvements in sustained disease remission and...
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
16 days ago
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary...
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
24 days ago
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color...
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
29 days ago
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP...
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
29 days ago
Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to...
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
about 1 month ago
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or...
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
about 1 month ago
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in...
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
about 1 month ago
First results to be presented in two ASCO oral presentations Data in...
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
about 1 month ago
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize...
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
about 2 months ago
Adam Kovalčík , 19, receives $100,000 Top Award for his development of...